Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage

Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage
Janssen Biotech plans a Phase 1 clinical trial of a therapy that its partner Ionis Pharmaceuticals developed as a treatment for gastrointestinal immune disorders. Under their collaboration agreement, Ionis received $5 million for bringing the therapy, IONIS-JBI 1-2.5 Rx, to the clinical-trial stage. Janssen is responsible for obtaining regulatory approval of the treatment worldwide, and commercializing it. Ionis stands to gain up to $585 million more in milestone payments and license fees. It will also receive a percentage of the sales of any product that reaches the market. Ionis specializes in RNA-focused
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *